| Muscular Dystrophy, Duchenne
Viltepso vs Amondys 45
Side-by-side clinical, coverage, and cost comparison for muscular dystrophy, duchenne.Deep comparison between: Viltepso vs Amondys 45 with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsAmondys 45 has a higher rate of injection site reactions vs Viltepso based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Amondys 45 but not Viltepso, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Viltepso
Amondys 45
At A Glance
IV infusion
Once weekly
Antisense oligonucleotide (PMO)
IV infusion
Once weekly
Antisense oligonucleotide (exon 45 skipper)
Indications
- Muscular Dystrophy, Duchenne
- Muscular Dystrophy, Duchenne
Dosing
Muscular Dystrophy, Duchenne 80 mg/kg once weekly as a 60-minute IV infusion; serum cystatin C, urine dipstick, and urine protein-to-creatinine ratio should be measured before starting.
Muscular Dystrophy, Duchenne 30 mg/kg once weekly as a 35 to 60-minute IV infusion via an in-line 0.2 micron filter.
Contraindications
—
- Known serious hypersensitivity to casimersen or to any of the inactive ingredients in AMONDYS 45
Adverse Reactions
Most common (>=15%) Upper respiratory tract infection, injection site reaction, cough, pyrexia
Common (>=10%) Contusion, arthralgia, diarrhea, vomiting, abdominal pain, ejection fraction decreased, urticaria
Most common (>=20%) Upper respiratory tract infections, cough, pyrexia, headache, arthralgia, oropharyngeal pain
Serious Hypersensitivity reactions including angioedema and anaphylaxis
Postmarketing Infusion-related reactions including rash, headache, cough, abdominal pain, and vomiting; hypersensitivity reactions including angioedema and anaphylaxis
Pharmacology
Viltolarsen is an antisense oligonucleotide (phosphorodiamidate morpholino oligomer subclass) that binds to exon 53 of dystrophin pre-mRNA, causing exon 53 skipping during mRNA processing and enabling production of an internally truncated dystrophin protein in patients with DMD gene mutations amenable to exon 53 skipping.
Casimersen is an antisense oligonucleotide (phosphorodiamidate morpholino oligomer subclass) that binds to exon 45 of dystrophin pre-mRNA, causing exon 45 skipping and production of an internally truncated dystrophin protein in patients with DMD mutations amenable to exon 45 skipping.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Viltepso
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (0/12)
Amondys 45
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (0/12)
UnitedHealthcare
Viltepso
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Amondys 45
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Viltepso
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (0/3)
Amondys 45
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Duchenne Muscular Dystrophy
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAssistance Fund: Duchenne Muscular Dystrophy
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
ViltepsoView full Viltepso profile
Amondys 45View full Amondys 45 profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.